Linked Life Data

19453397

Source:http://linkedlifedata.com/resource/pubmed/id/19453397

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2009-5-20
pubmed:abstractText
FluBlok, a recombinant trivalent hemagglutinin (HA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg-based trivalent inactivated influenza vaccine (TIV) manufacturing process. FluBlok contains three times more HA than TIV and does not contain egg-protein or preservatives. This review discusses the four main clinical studies that were used to support licensure of FluBlok under the 'Accelerated Approval' mechanism in the United States.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1750-2659
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
211-9
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
FluBlok, a recombinant hemagglutinin influenza vaccine.
pubmed:affiliation
Protein Sciences Corporation, 1000 Research Parkway, Meriden, CT 06450, USA. manon.cox@proteinsciences.com
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Review, Multicenter Study